Toxic epidermal necrolysis: 13 years of experience in the management at a Department of Dermatology in China

References

• Stella M, Clemente A, Bollero D, et al Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach: a retrospective analysis. Burns 2007;33:452–459
   PubMed Web of Science ®Google Scholar
• Chan H-L, Stern RS, Arndt KA, et al The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43–47
   PubMed Web of Science ®Google Scholar
• Palmieri T, Greenhalgh D, Saffle J, et al A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century. J Burn Care Res 2002;23:87–96
   Web of Science ®Google Scholar
• Gravante G, Delogu D, Marianetti M, et al Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome. Eur Rev Med Pharmacol Sci 2007;11:119
   PubMed Web of Science ®Google Scholar
• Gerdts B, Vloemans A, Kreis R. Toxic epidermal necrolysis: 15 years' experience in a Dutch burns centre. J Eur Acad Dermatol Venereol 2007;21:781–788
   PubMed Web of Science ®Google Scholar
• Heimbach DM, Engrav LH, Marvin JA, et al Toxic epidermal necrolysis. A step forward in treatment. JAMA 1987;257:2171–2175
   PubMed Web of Science ®Google Scholar
• Letko E, Papaliodis DN, Papaliodis GN, et al Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005;94:419–436
   PubMed Web of Science ®Google Scholar
• Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 2003;139:39–43
   PubMed Web of Science ®Google Scholar
• Auquier-Dunant A, Mockenhaupt M, Naldi L, et al Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019–1024
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Fouchard N, Bertocchi M, et al SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149–153
   PubMed Web of Science ®Google Scholar
• Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004;140:890–892
   PubMedGoogle Scholar
• Valeyrie‐Allanore L, Wolkenstein P, Brochard L, et al Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010;163:847–853
   PubMed Web of Science ®Google Scholar
• Firoz BF, Henning JS, Zarzabal LA, Pollock BH. Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol 2012;67:630–635
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Rzany B, Stern RS, et al Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92–96
   PubMed Web of Science ®Google Scholar
• Pezzini C, Ciocca O, Valvo B, Vassallo C. Sindrome di Stevens-Johnson/Necrolisi Epidermica Tossica (SJS/TEN): difficoltà diagnostiche e terapeutiche in un paziente affetto da linfoma B. Bollettino della Società Medico Chirurgica di Pavia. 2014;126:743–749
   Google Scholar
• Jensen AG, Wachmann CH, Poulsen KB, et al Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med 1999;159:1437–1444
   PubMedGoogle Scholar
• Viard I, Wehrli P, Bullani R, et al Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490–493
   PubMed Web of Science ®Google Scholar
• Trice S, Melnik G, Page CP. Complications and costs of early postoperative parenteral versus enteral nutrition in trauma patients. Nutr Clin Pract 1997;12:114–119
   Google Scholar
• Nassif A, Bensussan A, Boumsell L, et al Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209–1215
   PubMed Web of Science ®Google Scholar
• Paul C, Wolkenstein P, Adle H, et al Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br. J. Dermatol 1996;134:710–714
   PubMed Web of Science ®Google Scholar
• Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013;69:173.e1–e13
   PubMedGoogle Scholar
• Tripathi A, Ditto AM, Grammer LC, et al Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000;21:101–105
   PubMed Web of Science ®Google Scholar
• Halebian PH, Corder VJ, Madden MR, et al Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503–512
   PubMed Web of Science ®Google Scholar
• Paquet P, Piérard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005;136:205–216
   PubMed Web of Science ®Google Scholar
• Webb A, Barclay S, Bennett E. In vitro colloid osmotic pressure of commonly used plasma expanders and substitutes: a study of the diffusibility of colloid molecules. Intensive Care Med 1989;15:116–120
   PubMed Web of Science ®Google Scholar
• Egan CA, Grant WJ, Morris SE, et al Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999;40:458–461
   PubMed Web of Science ®Google Scholar
• Zhang A, Sun H, Wang Z, et al Metabolomics: towards understanding traditional Chinese medicine. Planta Med 2010;76:2026–2035
   PubMed Web of Science ®Google Scholar
• Chan K. Chinese medicinal materials and their interface with Western medical concepts. J Ethnopharmacol 2005;96:1–18
   PubMed Web of Science ®Google Scholar
• Ramakrishna V, Setty O. Safety, efficacy and preclinical evaluation of plant products. In: Compendium of bioactive natural products book series. Houston, TX: Studium Press, LLC; 2009;3:124–146
   Google Scholar
• Saw CLL, Wu Q, Su ZY, et al Effects of natural phytochemicals in Angelica sinensis (Danggui) on Nrf2‐mediated gene expression of phase II drug metabolizing enzymes and anti‐inflammation. Biopharm Drug Dispos 2013;34:303–311
   PubMed Web of Science ®Google Scholar
• Han C, Guo J. Antibacterial and anti-inflammatory activity of traditional Chinese herb pairs, Angelica sinensis and Sophora flavescens. Inflammation 2012;35:913–919
   PubMed Web of Science ®Google Scholar
• Chen X, Howard OZ, Yang X, et al Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function. Life Sci 2002;70:2897–2913
   PubMed Web of Science ®Google Scholar
• Cheng F, Zhong X, Lu Y, et al Refined Qingkailing protects MCAO mice from endoplasmic reticulum stress-induced apoptosis with a broad time window. Evid-Based Complement Alternat Med 2012;2012
   Google Scholar
• Li X, Zhang C, Shi Q, et al Improving the efficacy of conventional therapy by adding andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease: a randomized controlled trial. Evid Based Complement Alternat Med 2013;2013:87–96
   Google Scholar
• Sinha J, Mukhopadhyay S, Das N, Basu MK. Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo. Drug Deliv 2000;7:209–213
   PubMed Web of Science ®Google Scholar
• Wehrli P, Viard I, Bullani R, et al Death receptors in cutaneous biology and disease. J Invest Dermatol 2000;115:141–148
   PubMed Web of Science ®Google Scholar
• Spornraft-Ragaller P, Theilen H, Gottschlich G, Ragaller M. Behandlung der toxischen epidermalen Nekrolyse. Hautarzt 2006;57:185–194
   PubMed Web of Science ®Google Scholar
• Prins C, Kerdel FA, Padilla RS, et al Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26–32
   PubMed Web of Science ®Google Scholar
• Bachot N, Revuz J, Roujeau J-C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33–36
   PubMedGoogle Scholar
• Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, et al Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006;126:272–276
   PubMed Web of Science ®Google Scholar